Marksans Pharma Gains Marketing Authorization for Exemestane
Filing Summary
Marksans Pharma Ltd announced that its wholly owned subsidiary, Relonchem Ltd, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its Exemestane 25mg film-coated tablets. This authorization allows Relonchem to market the product in the UK. The announcement was made on November 5, 2025. Marksans Pharma is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations globally, with facilities approved by leading regulatory agencies.
Marksans Pharma Ltd announced that its wholly owned subsidiary, Relonchem Ltd, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product, Exemestane 25mg film-coated tablets. The authorization permits Relonchem to market this product in the UK.
The announcement was made on November 5, 2025. This development is part of Marksans Pharma’s ongoing efforts to expand its product offerings in the global pharmaceutical market.
Marksans Pharma is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations worldwide. The company’s manufacturing facilities are located in India, the USA, and the UK, and are approved by several leading regulatory agencies, including the USFDA, UKMHRA, and Australian TGA. Marksans Pharma’s product portfolio covers major therapeutic segments such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies. The company markets these products globally.